Department of Medicine, Division of Nephrology and Hypertension, University of California, San Diego, La Jolla, CA 92093, USA.
Bioorg Med Chem. 2011 Jun 1;19(11):3320-40. doi: 10.1016/j.bmc.2011.04.045. Epub 2011 Apr 28.
Organic anion transporter 1 (Oat1), first identified as NKT, is a multispecific transporter responsible for the handling of drugs and toxins in the kidney and choroid plexus, but its normal physiological role appears to be in small molecule metabolite regulation. Metabolites transported by Oat1 and which are altered in the blood and urine of the murine Oat1 knockout, may serve as templates for further drug design. This may lead to better tissue targeting of drugs or design of Oat1 inhibitors that prolong the half-life of current drugs. Due to the multispecificity of the transporter, 19 of known targeted metabolites have different chemical structures and properties that make constructing a common pharmacophore model difficult. Here we propose an approach that clustered the metabolites into four distinct groups which allowed for the construction of a consensus pharmacophore for each cluster. The screening of commercial molecular databases determined the top candidates whose interaction with Oat1 was confirmed in an experimental model of organic anion transport. Thus, these candidate selections represent potential molecules for further drug design.
有机阴离子转运蛋白 1(Oat1),最初被鉴定为 NKT,是一种多特异性转运蛋白,负责肾脏和脉络丛中药物和毒素的处理,但它的正常生理作用似乎在于调节小分子代谢物。Oat1 转运的代谢物以及在 Oat1 敲除小鼠的血液和尿液中改变的代谢物,可以作为进一步药物设计的模板。这可能导致药物更好地靶向组织,或者设计出延长现有药物半衰期的 Oat1 抑制剂。由于转运体的多特异性,19 种已知的靶向代谢物具有不同的化学结构和性质,这使得构建通用药效团模型变得困难。在这里,我们提出了一种将代谢物聚类成四个不同组的方法,从而可以为每个组构建共识药效团。对商业分子数据库的筛选确定了候选药物,其与 Oat1 的相互作用在有机阴离子转运的实验模型中得到了证实。因此,这些候选药物的选择代表了进一步药物设计的潜在分子。